Although endothelin-1 (ET-1) induces vasoconstriction, it remains unknown whether 17␤-estradiol (E2) treatment following trauma-hemorrhage alters these ET-1-induced vasoconstrictive effects. In addition, the role of the specific estrogen receptor (ER) subtypes (ER-␣ and ER-␤) and the endothelium-localized downstream mechanisms of actions of E2 remain unclear. We hypothesized that E2 attenuates increased ET-1-induced vasoconstriction following trauma-hemorrhage via an ER-␤-mediated pathway. To study this, aortic rings were isolated from male SpragueDawley rats following trauma-hemorrhage with or without E2 treatment, and alterations in tension were determined in vitro. Doseresponse curves to ET-1 were determined, and the vasoactive properties of E2, propylpyrazole triol (PPT, ER-␣ agonist), and diarylpropionitrile (DPN, ER-␤ agonist) were determined. The results showed that trauma-hemorrhage significantly increased ET-1-induced vasoconstriction; however, administration of E2 normalized ET-1-induced vasoconstriction in trauma-hemorrhage vessels to the shamoperated control level. The ER-␤ agonist DPN counteracted ET-1-induced vasoconstriction, whereas the ER-␣ agonist PPT was ineffective. Moreover, the vasorelaxing effects of E2 were not observed in endothelium-denuded aortic rings or by pretreatment of the rings with a nitric oxide (NO) synthase inhibitor. Cyclooxygenase inhibition with indomethacin had no effect on the action of E2. Thus, E2 administration attenuates ET-1-induced vasoconstriction following trauma-hemorrhage via an ER-␤-mediated pathway that is dependent on endothelium-derived NO synthesis. estrogen receptor; nitric oxide; endothelium; aortic ring IT IS WELL ESTABLISHED THAT sex difference influences cardiovascular and immunological responsiveness via sex hormones, which have potent vasoactive properties (3, 20, 24, 27, 32, 34) . In this regard, the beneficial effects of 17␤-estradiol (E 2 ) administration have been demonstrated by improvement in organ perfusion and function under a range of conditions (3) (4) (5) 25) . These studies and others (3, 9, 11) have led to the development of the concept that treatment of male trauma victims with estrogenic compounds can alleviate or attenuate the physiological and immunological derangements associated with such injury.
IT IS WELL ESTABLISHED THAT sex difference influences cardiovascular and immunological responsiveness via sex hormones, which have potent vasoactive properties (3, 20, 24, 27, 32, 34) . In this regard, the beneficial effects of 17␤-estradiol (E 2 ) administration have been demonstrated by improvement in organ perfusion and function under a range of conditions (3) (4) (5) 25) . These studies and others (3, 9, 11) have led to the development of the concept that treatment of male trauma victims with estrogenic compounds can alleviate or attenuate the physiological and immunological derangements associated with such injury.
Estrogen can improve circulation via vasodilatation induced by either prostacyclin or nitric oxide (NO) synthesis and/or by decreasing the production of vasoconstrictor agents, such as endothelin or angiotensin II (4, 27, 30) . ET-1 is a potent vasoactive peptide produced by vascular endothelial cells and exerts its vasoconstrictor effects locally on the underlying vascular smooth muscle cells (31) . The effects of E 2 on ET-1-mediated vasoconstriction are mediated through downstream mechanisms that are induced by estrogen receptor (ER) activation. In this regard, two major subtypes of ERs have been identified, ER-␣ and ER-␤ (21, 35) . Although studies have demonstrated that vascular endothelial cells and myocytes express both the ER-␣ and ER-␤ subtypes, their expression has been shown to be species, sex, and organ specific. Moreover, studies (15, 17, 19) have reported both endothelium-dependent and -independent vasodilator responses to E 2 , thereby further complicating the identification of downstream mechanisms responsible for E 2 action. Our recent study (37) has shown that E 2 can reduce ET-1-induced vasoconstriction. Nonetheless, the relative contributions of ER subtypes and downstream mechanisms remain to be elucidated. The present study was directed at examining the contribution of ER subtypes and the effector mechanisms involved in E 2 -mediated modulation of ET-1-induced vasoconstriction following trauma-hemorrhage.
MATERIALS AND METHODS
Animals and model of trauma-hemorrhage. Adult male SpragueDawley rats (Charles River, Wilmington, MA), weighing 275-325 g, were studied. Animals were fasted 16 h before the experiment but were allowed water ad libitum. The Institutional Animal Care and Use Committee of the University of Alabama at Birmingham approved this project. The animals were anesthetized with 1.5% isoflurane with air inhalation and underwent a 5-cm ventral midline laparotomy to induce tissue trauma before the onset of hemorrhage. Both femoral arteries and one femoral vein were cannulated with polyethylene (PE-50) tubing for bleeding, monitoring of mean arterial pressure, and fluid resuscitation. The animals were then restrained in a supine position and the areas of incision bathed with 1% lidocaine (ElkinsSinn, Cherry Hill, NJ) to minimize postoperative pain. After the procedure, anesthesia was removed, and, when the mean arterial pressure reached ϳ120 mmHg, the animals were bled to a pressure of 40 mmHg (i.e., severe hypotension) within 10 min. The blood pressure of 40 mmHg was maintained by removing more blood until the animal was no longer able to maintain blood pressure (i.e., maximum bleed out). Blood pressure was then maintained by infusing Ringer lactate (RL) intravenously until 40% of the shed blood volume was returned. The animals were resuscitated with four times the volume of maximum bleed out with RL over a period of 60 min at a constant rate. Following resuscitation, the catheters were removed, the vessels were ligated, and skin incisions were closed with sutures. Animals were maintained conscious and without heparin injection throughout the hemorrhage and resuscitation procedure. Blood pressure was monitored with a Blood Pressure Analyzer (Digi-Med, Louisville, KY), and the resuscitation perfusion pump was a Harvard Apparatus Pump 11 (Holliston, MA). Sham-operated animals underwent the same surgical procedure but were neither bled nor resuscitated. The time required for maximum bleed out was ϳ45 min; the volume of maximum bleed out was ϳ60% of the calculated circulating blood volume. 17␤-Estradiol water soluble (E 2, 1.0 mg/kg; Sigma, St. Louis) or the same volume of vehicle was applied intravenously at the beginning of resuscitation.
Aortic ring preparation. At 2 h after resuscitation, rats were anesthetized by 1.5% isoflurane inhalant before surgery. The chests were opened, and thoracic aortas were isolated and rapidly removed. The isolated thoracic aorta was immediately immersed in KrebsRinger HCO 3 solution containing (in mM) 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 Ca-EDTA, and 11.1 glucose, which was aerated with 95% O2-5% CO2 (pH ϭ 7.4; PO 2 ϭ 580 mmHg). The thoracic aorta was trimmed carefully to prevent damage to the endothelial cells and cut into rings of ϳ2.5 mm in length. The aortic ring was mounted on two specimen holders and placed in a glass organ chamber containing 20 ml of aerated KrebsRinger HCO 3 solution at 37°C. One holder was stationary, whereas the other was connected to an isometric force displacement transducer (model FT03, Grass Instruments, Quincy, MA) coupled to a calibrated polygraph (model 7D, Grass Instruments).
Determination of ET-1-induced vessel constriction. The aortic rings were incubated for 60 min at a tension of 1.0 g, during which time the organ chamber was rinsed every 15 min with the aerated KrebsRinger-HCO 3 buffer. When basal tension became stable, the recording pen was adjusted to baseline as zero tension. The ET-1 doseresponse curves were then performed. The dose-response curve to ET-1 was evaluated by using ascending doses of ET-1 (diluted freshly in normal saline; American Peptide, Sunnyvale, CA), resulting in a 0 to 100 ng/ml final concentration in the organ bath. The length of time between the subsequent doses (ϳ5-10 min) was dependent on the development of maximal tension by the preceding ET-1 dose.
Evaluation of the vessel relaxation capacity of E 2, diarylpropionitrile and propylpyrazole triol. As described in Determination of ET-1-induced vessel constriction, the aortic ring was prepared and incubated in the organ bath. When basal tension was stable, the recording pen was adjusted to zero as baseline tension. A 5 ϫ 10 Ϫ8 M dose of ET-1 was added to the bath to induce vasoconstriction at a tension of ϳ1.0 g. Once maximal ET-1-induced tension was induced, E 2, diarylpropionitrile (DPN, ER-␤ agonist; Tocris-Cookson, Ellisville, MO), or propylpyrazole triol (PPT, ER-␣ agonist; TocrisCookson) was added to the bath in ascending doses (10 Ϫ9 -10 Ϫ5 M). The next dose of the series was added once maximal relaxation of the previous dose had been established and tension was stable. The relaxations were expressed as a percent decrease from the maximal ET-1-induced tension. Water-soluble E 2 was dissolved in saline. DPN and PPT were dissolved in ethanol as stock solution in a 10 Ϫ2 M concentration and were then further diluted in Krebs-Ringer-HCO 3 buffer.
The effects of E 2 on ET-1-induced vasoconstriction in intact and endothelium-denuded aortic rings. To study the role of the endothelium on E 2-mediated attenuation in ET-1-induced vasoconstriction, ET-1 dose-response curves were carried out on E 2-preincubated intact or endothelial cell-denuded aortic rings. Endothelial cells were denuded mechanically without damage to the smooth muscle. The completion of endothelial denudation was verified by a lack of acetylcholine-induced relaxation (i.e., endothelium cell dependent), and the concurrent integrity of smooth muscle response was verified by nitroglycerine-induced relaxation (i.e., smooth muscle dependent). Water-soluble E2 (Sigma) was dissolved in saline, and a final concentration of 10 Ϫ5 M E2 in the organ bath was added at 20 min before the ET-1 dose-response curves were performed.
Evaluation of the role of NO and ecosinoids in E 2-mediated vasorelaxation.
To examine the role of NO and prostacyclin pathway on E2-mediated vasodilatation, the effects of N -nitro-L-arginine (L-NNA, NO synthase inhibitor; Sigma) or indomethacin, (cyclooxygenase-2 inhibitor; Sigma) on E 2-mediated attenuation in ET-1-induced vasoconstriction were also investigated. Aortic rings were prepared as described in Aortic ring preparation, and a final concentration of 10
Ϫ4
M of L-NNA or indomethacin was applied 20 min before E 2 (10 Ϫ5 M) treatment. Twenty minutes thereafter, after the baseline was stabilized and adjusted to zero, a dose-response curve was performed by adding ET-1 (5 ϫ 10 Ϫ11 -5 ϫ 10 Ϫ8 M) to the organ bath. Immunohistochemical staining for ER-␣ and ER-␤. The rat thoracic aortic vessel was rapidly removed from the chest and fixed in 4% paraformaldehyde and embedded in paraffin. Paraffin-embedded tissues were cross-sectioned at 4 m thickness, and the sections were deparaffinized through xylene and rehydrated through a series of alcohols. Treating the sections with 0.3% hydrogen peroxidase for 30 min inhibited endogenous peroxidase activity. Primary antibodies ER-␣ (MC-20), rabbit polyclonal antibody, or ER-␤ (Y-19), goat polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), were both applied at 1 g/ml and incubated at 4°C overnight. Incubation of ER-␣ was followed by an addition of a secondary antibody, biotinylated anti-rabbit IgG, whereas ER-␤ was followed by incubation with biotinylated anti-goat IgG secondary antibody for 1 h at room temperature. Horseradish peroxidase-conjugated streptavidin (Vectastain kits, Vector) was applied for 30 min at room temperature. All dilutions were based on the manufacturer's instructions. Peroxidase was visualized using 3,3Ј-diaminobenzidine hydrochloride (Vector). The nucleus was visualized by staining with hematoxylin. For control sections, primary antibodies were omitted and replaced by buffer.
Statistical analysis. All data are presented as means Ϯ SE. Statistical differences among groups were determined by one-way ANOVA, followed by Tukey's test. Differences were considered significant if P Ͻ 0.05.
RESULTS
The influence of E 2 on ET-1-induced vasoconstriction. As shown in Fig. 1A , the aortic vasoconstrictions induced by ET-1 (1.0 -100 ng/ml) were significantly increased (P Ͻ 0.05) following trauma-hemorrhage compared with the sham-operated group; however, this increase was not observed in the E 2 -treated trauma-hemorrhage group. Moreover, as shown in Fig.  1B , the aortic vasorelaxation induced by E 2 (10 Ϫ7 -10 Ϫ5 M) was significantly attenuated (P Ͻ 0.05) following traumahemorrhage compared with the sham-operated group. E 2 treatment prevented this attenuation in vasorelaxation in the traumahemorrhage group.
The role of ER subtypes in E 2 -induced vasorelaxation. To determine the contribution of the ␣-and ␤-subtypes of ER in the E 2 -mediated vasorelaxation, the vessel relaxing capacities of DPN (ER-␤ agonist) or PPT (ER-␣ agonist) were investigated following ET-1-induced vasoconstriction. The results in Fig. 2A show that between the concentration ranges of 10 Ϫ8 and 10 Ϫ6 M, DPN (the ER-␤ agonist) attenuated vascular tension 82.5 Ϯ 9.3% in ET-1-preconstricted aortic rings from sham-operated rats. DPN vasorelaxing properties were significantly less in the trauma-hemorrhage group compared with those in the sham-operated group. However, DPN attenuated vascular tensions to a comparable degree in the shamoperated and trauma-hemorrhage E 2 groups at a concentration of 10 Ϫ6 M. Within the concentration range of 10 Ϫ8 -10 Ϫ5 M, PPT (the ER-␣ agonist) failed to result in signifi-cant vasorelaxation of ET-1-preconstricted aortic ring from all of three groups (Fig. 2B) . Fig. 3 show that E 2 attenuated ET-1-induced constriction of aortic rings with intact endothelium; however, ET-1-induced vasoconstriction was not altered by E 2 pretreatment in denuded aortic rings. Following administration of ET-1 (0 -50 nM), the elevation in tension was significantly greater in the vascular rings denuded of endothelium compared with intact vascular rings (Fig. 3) . To evaluate the relative contribution of NO and cyclooxygenase derivatives in the E 2 -induced vasorelaxation, the NO synthase inhibitor L-NNA or the cyclooxygenase inhibitor indomethacin were added to the organ baths before E 2 administration. Administration of L-NNA prevented the E 2 -induced relaxation of ET-1-constricted aortic rings, whereas preincubation with the cyclooxygenase inhibitor indomethacin had no influence on E 2 -induced vasorelaxation (Fig. 4) . Fig. 5 show the immunohistochemical staining of ER-␣ and ER-␤ in representative aortic vessels. The brown color is indicative of specific staining of ER-␣ or ER-␤. It can be seen that the dark brown stain is localized to the endothe- lium as opposed to the smooth muscle (Fig. 5A ) or ER-␤ (Fig.  5B) . Brown color is absent in sections used for control staining for ER-␣ (Fig. 5C ) or ER-␤ (Fig. 5D) .
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DISCUSSION
There is a growing body of evidence that indicates that E 2 administration improves organ perfusion and function following low-flow conditions or an ischemic insult (13, 37) . Among the mechanisms, the attenuation of endothelin release has been implicated as a significant contributor to the E 2 -mediated salutary effects on organ function (4, 37) . The finding of the present study provides further evidence that estradiol not only reduces ET-1 production but also inhibits its vasoconstrictive action on the vasculature. Although a recent study from our laboratory has reported a reduced response to exogenous ET-1 following E 2 treatment, it should be noted that those studies were carried out on portal circulation (37), a vascular bed that differs markedly from the aortic vasculature.
Previous studies (18, 25, 37 ) from our laboratory have also shown salutary effects of E 2 and its derivatives in restoring organ functions following trauma-hemorrhage. Furthermore, it has been demonstrated that trauma-hemorrhage-induced ET-1 release in proestrus female rats, which have elevated estrogen levels, remained at significantly lower levels than in their male counterparts (4). This sex dimorphism was also reflected in the inverse correlation of endogenous plasma ET-1 and E 2 levels. Estrogens mediate their biological effects via different receptor subtypes. To date, three ER subunits have been identified: ER-␣, ER-␤, and ER-␥. The biological relevance for only the ER-␣ and ER-␤ subtypes has been described (16, 22, 28) , whereas very little is known about ER-␥. Vascular endothelium and myocytes express both ER-␣ and ER-␤, and their local distribution is dependent on both sex difference and anatomical location. Previous studies have shown both ER-␣ and ER-␤ expression in the rat aorta (2, 23, 29) . In the present study, using immunohistochemistry, we have demonstrated that both ER-␣ and ER-␤ are present in the rat aorta and are localized to the endothelial cells. However, in mesenteric arteries, PPT, the ER-␣ agonist, was found to be more effective in inducing acute relaxation than DPN, the ER-␤ agonist (26) , suggesting a preponderance of ER-␣ in that vascular bed.
Estrogen has been reported to induce NO production through phosphorylation-dependent processes; however, the precise pathways responsible for endothelial NO synthase activation have not been fully elucidated (14, 33) . Some studies (10, 12) suggest that the acute effects of E 2 on NO synthase activity and NO production are mediated via ER-␣ activation. In contrast, Chambliss et al. (8) reported that overexpression of ER-␤ enhanced endothelial NO synthase activation by E 2 . In contrast, mice deficient in ER-␤ display multiple functional abnormalities, and Zhu et al. (38) have suggested an essential role for ER-␤ in the regulation of vascular function and blood pressure. NO can also counteract ET-1-mediated vasoconstriction via guanylate-cyclase activation and reduced endothelin receptor affinity (36) . Our present study also suggests that ER-␤ plays an important role in E 2 -mediated vasorelaxation. The present study indicates that while both ER-␣ and ER-␤ are present on the aortic endothelium, the ability of the ER-␤, but not the ER-␣, agonist to induce vasorelaxation indicates that the acute effects of E 2 on NO synthase activity and NO production are mediated via ER-␤, and not ER-␣, activation. Findings by Al Zubair et al. (1) are consistent with our findings here. They observed that in rat aortic rings contracted with KCl, the ER-␤ agonist DPN produced significantly greater relaxations than the ER-␣ agonist PPT. In contrast, Bolego et al. (6) reported that aortic rings isolated from E 2 -treated ovariectomized rats responded with higher potency to an ER-␣ agonist than an ER-␤ agonist. The apparent discrepancy between the results of Bolego et al. (6) and our findings may be related to the use of different sexes, treatment regimen, and differences in ER-subtype predominance and/or connecting downstream mechanisms that can modify responses to ER agonists.
In our experiments, E 2 , the ER-␤ agonist DPN, but not the ER-␣ agonist PPT, attenuated the ET-1-induced vasoconstriction. The lack of effectiveness of PPT suggests that the role of ER-␤ subtype is predominant in our experimental settings. The abolishment of E 2 -induced vasodilatation by endothelial cell denudation underlines the endothelial source as key elements participating in this process. Furthermore, the elimination of E 2 -induced effects with NO synthase, but not cyclooxygenase, inhibition indicates that NO, but not prostacyclin, plays a crucial role in E 2 -mediated vasoactivity. Since it has been reported that indomethacin inhibition results in increased NO production, it is possible that indomethacin treatment eliminates the negative feedback of prostacyclin on NO production, and thus the increased NO release can compensate for the lack of prostacyclin-induced vasodilator effect (7) . It should, however, be emphasized that the current study examined only the acute effects of E 2 on vascular reactivity. It is plausible that receptor expression and other components of signal transduction and cellular activation are altered by chronic administration of E 2 .
The interest in the effects of estrogen of vascular reactivity in males is related to the development of the concept that treatment of males in hemorrhagic shock estrogens or related compounds can prevent the deleterious consequences of this form of injury (3, 9, 11) . Experimental studies have shown that the use of estrogens and/or androgen antagonists as salutary adjuncts, without any adverse effects on gastrointestinal, hepatic, and renal functions, can normalize immunological and physiological responses after trauma-hemorrhage (3, 9, 11) and, therefore, would appear to be advantageous for the treatment of such derangements after severe blood loss in male trauma victims. In conclusion, our findings provide additional insights into the underlying mechanisms responsible for E 2 -induced maintenance of organ function under pathophysiological conditions.
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